Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Saved in:
| Title: | Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. |
|---|---|
| Authors: | Einerhand SMH; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Black AJ; Vancouver Prostate Centre, Vancouver, Canada., Zargar H; Department of Urology, Western Health, Melbourne, Australia., Fairey AS; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.; University of Alberta, Edmonton, AB, Canada., Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA., Mir MC; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Krabbe LM; Department of Urology, University of Münster, Münster, Germany., Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA., Jacobson NE; University of Alberta, Edmonton, AB, Canada., Montgomery JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Vasdev N; Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Yu EY; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Xylinas E; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA., Kassouf W; Department of Surgery (Division of Urology), McGill University Health Centre, Montreal, QC, Canada., Dall'Era MA; Department of Urology, David Medical Center, University of California at David, Sacramento, CA, USA., Sridhar SS; Princess Margaret Hospital, Toronto, ON, Canada., McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Aning J; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Shariat SF; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA.; Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria., Wright JL; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA., Bivalacqua TJ; Division of Urology, University of Pennsylvania, Pennsylvania, PA, USA., North S; Cross Cancer Institute, Edmonton, AB, Canada., Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Lotan Y; Department of Urology, University of Texas Southern Medical Center, Dallas, TX, USA., Grivas P; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Garcia JA; Department of Medicine, Case Comprehensive Cancer Center, Cleveland, USA., Stephenson AJ; Division of Urology, Rush University Medical Center, Chicago, IL, USA., Shah JB; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA., Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA., Zargar-Shoshtari K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., van Rhijn BWG; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany., Black PC; Vancouver Prostate Centre, Vancouver, Canada., Mertens LS; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. l.mertens@nki.nl. |
| Source: | World journal of urology [World J Urol] 2022 Nov; Vol. 40 (11), pp. 2707-2715. Date of Electronic Publication: 2022 Sep 28. |
| Publication Type: | Multicenter Study; Journal Article |
| Journal Info: | Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1433-8726 |
|---|---|
| DOI: | 10.1007/s00345-022-04160-7 |
